Literature DB >> 17484631

Measurement of calcitonin by immunoassay analyzers.

Christian Bieglmayer1, Heinrich Vierhapper, Robert Dudczak, Bruno Niederle.   

Abstract

BACKGROUND: Since Nichols Institute Diagnostics (NID) ended production of their automated calcitonin immunoassay, evaluation of an alternative calcitonin assay was necessary.
METHODS: Calcitonin measured by the NID procedure was compared with a test from Diagnostic Products Corporation (DPC). Calcitonin was also measured by assays from DiaSorin (DS) and Scantibodies (SC).
RESULTS: In 187 samples, detection failed either by NID (39%) or DPC (96%) assay; in 35% of samples, the tests agreed for non-measurable calcitonin. The regression line DPC=0.78 x NID-0.3 (r=0.998) fitted results from 236 samples with detectable calcitonin. A linear relationship, albeit with scattering at low concentrations, was observed. Importantly, stimulation by pentagastrin above basal calcitonin concentrations yielded similar results with both assays. Comparisons (DPC=0.80 x DS-3.4 and DPC=0.81 x SC-1.1) confirmed an aberrant calibration of the DPC test. To overcome the method bias, we propose a multiplication factor of 0.8 to convert NID to DPC results.
CONCLUSIONS: Apparently due to non-specific effects, the DS and SC assays produced calcitonin results in samples from completely thyroidectomized patients, while the DPC assay correctly failed to detect calcitonin. Thus, the DPC assay on an Immulite 2000 analyzer may be used as a more accurate substitute for NID if the different calibration is noted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484631     DOI: 10.1515/CCLM.2007.124

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

2.  Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.

Authors:  Cléber P Camacho; Susan C Lindsey; Maria Clara C Melo; Ji H Yang; Fausto Germano-Neto; Flávia de O F Valente; Thiago R N Lima; Rosa Paula M Biscolla; José G H Vieira; Janete M Cerutti; Magnus R Dias-da-Silva; Rui M B Maciel
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

3.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

4.  Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test".

Authors:  Martin B Niederle; Christian Scheuba; Alois Gessl; Shuren Li; Oskar Koperek; Christian Bieglmayer; Philipp Riss; Andreas Selberherr; Bruno Niederle
Journal:  Biochem Med (Zagreb)       Date:  2018-10-15       Impact factor: 2.313

5.  The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.

Authors:  Raymon H Grogan; Elliot J Mitmaker; Orlo H Clark
Journal:  Cancers (Basel)       Date:  2010-05-20       Impact factor: 6.639

6.  Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.

Authors:  Simona Censi; Marta Di Stefano; Andrea Repaci; Teresa Benvenuti; Jacopo Manso; Uberto Pagotto; Maurizio Iacobone; Susi Barollo; Loris Bertazza; Francesca Galuppini; Clara Benna; Gianmaria Pennelli; Mario Plebani; Diego Faggian; Carla Colombo; Laura Fugazzola; Caterina Mian
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-13       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.